Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus
Cell therapy is a progressively growing field that is rapidly moving from preclinical model development to clinical application. Outcomes obtained from clinical trials reveal the therapeutic potential of stem cell-based therapy to deal with unmet medical treatment needs for several disorders with no...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.01151/full |
id |
doaj-0f192f8d7457439b951bccfcc4c288ec |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bárbara Soria-Juan Natalia Escacena Vivian Capilla-González Yolanda Aguilera Lucía Llanos Juan R. Tejedo Juan R. Tejedo Francisco J. Bedoya Francisco J. Bedoya Verónica Juan Antonio De la Cuesta Rafael Ruiz-Salmerón Enrique Andreu Lukas Grochowicz Felipe Prósper Fermín Sánchez-Guijo Francisco S. Lozano Manuel Miralles Lourdes Del Río-Solá Gregorio Castellanos José M. Moraleda Robert Sackstein Mariano García-Arranz Damián García-Olmo Franz Martín Franz Martín Abdelkrim Hmadcha Abdelkrim Hmadcha Bernat Soria Bernat Soria Bernat Soria Collaborative Working Group “Noma Project Team” |
spellingShingle |
Bárbara Soria-Juan Natalia Escacena Vivian Capilla-González Yolanda Aguilera Lucía Llanos Juan R. Tejedo Juan R. Tejedo Francisco J. Bedoya Francisco J. Bedoya Verónica Juan Antonio De la Cuesta Rafael Ruiz-Salmerón Enrique Andreu Lukas Grochowicz Felipe Prósper Fermín Sánchez-Guijo Francisco S. Lozano Manuel Miralles Lourdes Del Río-Solá Gregorio Castellanos José M. Moraleda Robert Sackstein Mariano García-Arranz Damián García-Olmo Franz Martín Franz Martín Abdelkrim Hmadcha Abdelkrim Hmadcha Bernat Soria Bernat Soria Bernat Soria Collaborative Working Group “Noma Project Team” Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus Frontiers in Immunology cellular medicaments cell-based therapy clinical trials diabetes critical limb ischemia cost-effective |
author_facet |
Bárbara Soria-Juan Natalia Escacena Vivian Capilla-González Yolanda Aguilera Lucía Llanos Juan R. Tejedo Juan R. Tejedo Francisco J. Bedoya Francisco J. Bedoya Verónica Juan Antonio De la Cuesta Rafael Ruiz-Salmerón Enrique Andreu Lukas Grochowicz Felipe Prósper Fermín Sánchez-Guijo Francisco S. Lozano Manuel Miralles Lourdes Del Río-Solá Gregorio Castellanos José M. Moraleda Robert Sackstein Mariano García-Arranz Damián García-Olmo Franz Martín Franz Martín Abdelkrim Hmadcha Abdelkrim Hmadcha Bernat Soria Bernat Soria Bernat Soria Collaborative Working Group “Noma Project Team” |
author_sort |
Bárbara Soria-Juan |
title |
Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus |
title_short |
Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus |
title_full |
Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus |
title_fullStr |
Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus |
title_full_unstemmed |
Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus |
title_sort |
cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2019-06-01 |
description |
Cell therapy is a progressively growing field that is rapidly moving from preclinical model development to clinical application. Outcomes obtained from clinical trials reveal the therapeutic potential of stem cell-based therapy to deal with unmet medical treatment needs for several disorders with no therapeutic options. Among adult stem cells, mesenchymal stem cells (MSCs) are the leading cell type used in advanced therapies for the treatment of autoimmune, inflammatory and vascular diseases. To date, the safety and feasibility of autologous MSC-based therapy has been established; however, their indiscriminate use has resulted in mixed outcomes in preclinical and clinical studies. While MSCs derived from diverse tissues share common properties depending on the type of clinical application, they markedly differ within clinical trials in terms of efficacy, resulting in many unanswered questions regarding the application of MSCs. Additionally, our experience in clinical trials related to critical limb ischemia pathology (CLI) shows that the therapeutic efficacy of these cells in different animal models has only been partially reproduced in humans through clinical trials. Therefore, it is crucial to develop new research to identify pitfalls, to optimize procedures and to clarify the repair mechanisms used by these cells, as well as to be able to offer a next generation of stem cell that can be routinely used in a cost-effective and safe manner in stem cell-based therapies targeting CLI. |
topic |
cellular medicaments cell-based therapy clinical trials diabetes critical limb ischemia cost-effective |
url |
https://www.frontiersin.org/article/10.3389/fimmu.2019.01151/full |
work_keys_str_mv |
AT barbarasoriajuan costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT nataliaescacena costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT viviancapillagonzalez costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT yolandaaguilera costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT luciallanos costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT juanrtejedo costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT juanrtejedo costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT franciscojbedoya costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT franciscojbedoya costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT veronicajuan costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT antoniodelacuesta costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT rafaelruizsalmeron costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT enriqueandreu costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT lukasgrochowicz costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT felipeprosper costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT ferminsanchezguijo costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT franciscoslozano costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT manuelmiralles costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT lourdesdelriosola costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT gregoriocastellanos costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT josemmoraleda costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT robertsackstein costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT marianogarciaarranz costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT damiangarciaolmo costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT franzmartin costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT franzmartin costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT abdelkrimhmadcha costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT abdelkrimhmadcha costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT bernatsoria costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT bernatsoria costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT bernatsoria costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus AT collaborativeworkinggroupnomaprojectteam costeffectivesafeandpersonalizedcelltherapyforcriticallimbischemiaintype2diabetesmellitus |
_version_ |
1724740854329901056 |
spelling |
doaj-0f192f8d7457439b951bccfcc4c288ec2020-11-25T02:50:00ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-06-011010.3389/fimmu.2019.01151448441Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes MellitusBárbara Soria-Juan0Natalia Escacena1Vivian Capilla-González2Yolanda Aguilera3Lucía Llanos4Juan R. Tejedo5Juan R. Tejedo6Francisco J. Bedoya7Francisco J. Bedoya8Verónica Juan9Antonio De la Cuesta10Rafael Ruiz-Salmerón11Enrique Andreu12Lukas Grochowicz13Felipe Prósper14Fermín Sánchez-Guijo15Francisco S. Lozano16Manuel Miralles17Lourdes Del Río-Solá18Gregorio Castellanos19José M. Moraleda20Robert Sackstein21Mariano García-Arranz22Damián García-Olmo23Franz Martín24Franz Martín25Abdelkrim Hmadcha26Abdelkrim Hmadcha27Bernat Soria28Bernat Soria29Bernat Soria30Collaborative Working Group “Noma Project Team”Fundación Jiménez Díaz Health Research Institute, Madrid, SpainDepartment of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, SpainDepartment of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, SpainDepartment of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, SpainFundación Jiménez Díaz Health Research Institute, Madrid, SpainDepartment of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, SpainSpanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, SpainDepartment of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, SpainSpanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, SpainAndalusian eHealth Library, Sevilla, SpainUnidad de Isquemia Crónica de Miembros Inferiores, Hospital Victoria Eugenia de la Cruz Roja, Sevilla, SpainServicio de Cardiología, Hospital Universitario Virgen Macarena, Sevilla, SpainClínica Universidad de Navarra, Pamplona, SpainClínica Universidad de Navarra, Pamplona, SpainClínica Universidad de Navarra, Pamplona, SpainIBSAL-Hospital Universitario Salamanca, Salamanca, SpainIBSAL-Hospital Universitario Salamanca, Salamanca, SpainDepartment of Surgery, University of Valencia, Valencia, Spain0Cirugía Vascular, Hospital Universitario de Valladolid, Valladolid, Spain1Servicio Hematología y Hemoterapia, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain1Servicio Hematología y Hemoterapia, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain2Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United StatesFundación Jiménez Díaz Health Research Institute, Madrid, SpainFundación Jiménez Díaz Health Research Institute, Madrid, SpainDepartment of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, SpainSpanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, SpainDepartment of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, SpainSpanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, SpainDepartment of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, SpainSpanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain3ISABIAL and Institute of Bioengineering, University Miguel Hernández de Elche, Alicante, SpainCell therapy is a progressively growing field that is rapidly moving from preclinical model development to clinical application. Outcomes obtained from clinical trials reveal the therapeutic potential of stem cell-based therapy to deal with unmet medical treatment needs for several disorders with no therapeutic options. Among adult stem cells, mesenchymal stem cells (MSCs) are the leading cell type used in advanced therapies for the treatment of autoimmune, inflammatory and vascular diseases. To date, the safety and feasibility of autologous MSC-based therapy has been established; however, their indiscriminate use has resulted in mixed outcomes in preclinical and clinical studies. While MSCs derived from diverse tissues share common properties depending on the type of clinical application, they markedly differ within clinical trials in terms of efficacy, resulting in many unanswered questions regarding the application of MSCs. Additionally, our experience in clinical trials related to critical limb ischemia pathology (CLI) shows that the therapeutic efficacy of these cells in different animal models has only been partially reproduced in humans through clinical trials. Therefore, it is crucial to develop new research to identify pitfalls, to optimize procedures and to clarify the repair mechanisms used by these cells, as well as to be able to offer a next generation of stem cell that can be routinely used in a cost-effective and safe manner in stem cell-based therapies targeting CLI.https://www.frontiersin.org/article/10.3389/fimmu.2019.01151/fullcellular medicamentscell-based therapyclinical trialsdiabetescritical limb ischemiacost-effective |